Faculty of Health, Medicine and Life Sciences, Maastricht University, Maastricht, The Netherlands.
Eur J Cancer. 2013 Oct;49(15):3093-101. doi: 10.1016/j.ejca.2013.05.030. Epub 2013 Jun 22.
To evaluate trends in the risk of local recurrences after breast-conserving treatment (BCT) and to examine the impact of local recurrence (LR) on distant relapse-free survival in a large, population-based cohort of women aged ≤40 years with early-stage breast cancer.
All women (n=1143) aged ≤40 years with early-stage (pT1-2/cT1-2, N0-2, M0) breast cancer who underwent BCT in the south of the Netherlands between 1988 and 2010 were included. BCT consisted of local excision of the tumour followed by irradiation of the breast.
After a median follow-up of 8.5 (0.1-24.6)years, 176 patients had developed an isolated LR. The 5-year LR-rate for the subgroups treated in the periods 1988-1998, 1999-2005 and 2006-2010 were 9.8% (95% confidence interval (CI) 7.1-12.5), 5.9% (95% CI 3.2-8.6) and 3.3% (95% CI 0.6-6.0), respectively (p=0.006). In a multivariate analysis, adjuvant systemic treatment was associated with a reduced risk of LR of almost 60% (hazard ratio (HR) 0.42; 95%CI 0.28-0.60; p<0.0001). Patients who experienced an early isolated LR (≤5 years after BCT) had a worse distant relapse-free survival compared to patients without an early LR (HR 1.83; 95% CI 1.27-2.64; p=0.001). Late local recurrences did not negatively affect distant relapse-free survival (HR 1.24; 95% CI 0.74-2.08; p=0.407).
Local control after BCT improved significantly over time and appeared to be closely related to the increased use and effectiveness of systemic therapy. These recent results underline the safety of BCT for young women with early-stage breast cancer.
评估保乳治疗(BCT)后局部复发风险的趋势,并在一个大型基于人群的≤40 岁早期乳腺癌女性队列中,检查局部复发(LR)对远处无复发生存的影响。
纳入 1988 年至 2010 年期间在荷兰南部接受 BCT 的所有≤40 岁的早期(pT1-2/cT1-2,N0-2,M0)乳腺癌女性(n=1143)。BCT 包括肿瘤的局部切除,然后进行乳房照射。
中位随访 8.5(0.1-24.6)年后,176 例患者发生孤立性 LR。1988-1998 年、1999-2005 年和 2006-2010 年治疗亚组的 5 年 LR 率分别为 9.8%(95%CI 7.1-12.5)、5.9%(95%CI 3.2-8.6)和 3.3%(95%CI 0.6-6.0)(p=0.006)。多变量分析显示,辅助全身治疗与 LR 风险降低近 60%相关(风险比(HR)0.42;95%CI 0.28-0.60;p<0.0001)。与没有早期 LR 的患者相比,早期孤立性 LR(BCT 后≤5 年)的患者远处无复发生存较差(HR 1.83;95%CI 1.27-2.64;p=0.001)。晚期局部复发不会对远处无复发生存产生负面影响(HR 1.24;95%CI 0.74-2.08;p=0.407)。
BCT 后的局部控制随时间显著改善,且似乎与全身治疗的应用和疗效的提高密切相关。这些最新结果强调了 BCT 对早期乳腺癌年轻女性的安全性。